Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives

2016 Molina, 2008, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo Clin Proc, 83, 584, 10.1016/S0025-6196(11)60735-0 2016 Kay, 2017, Revisions to the Tumor, Node, Metastasis staging of lung cancer (8(th) edition): rationale, radiologic findings and clinical implications, World J. Radiol, 9, 269, 10.4329/wjr.v9.i6.269 The Netherlands Cancer Registry (NCR). Incidence of NSCLC. Available at: www.iknl.nl/nkr-cijfers. Howlader, 2013 Sun, 2016, Surgical treatment of early l stage lung cancer: what has changed and what will change in the future, Semin Respir. Crit. Care Med, 37, 708, 10.1055/s-0036-1592173 Postmus, 2017, Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, 28, iv1, 10.1093/annonc/mdx222 Rosen, 2016, The natural history of operable non-small cell lung cancer in the national cancer database, Ann. Thorac. Surg, 101, 1850, 10.1016/j.athoracsur.2016.01.077 Ginsberg, 1995, Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group, Ann. Thorac Surg, 60, 615, 10.1016/0003-4975(95)00537-U Ijsseldijk, 2020, Oncological outcomes of lobar resection, segmentectomy, and wedge resection for T1a non-small-cell lung carcinoma: a systematic review and meta-analysis, Semin Thorac. Cardiovasc. Surg., 32, 582, 10.1053/j.semtcvs.2019.08.004 Winckelmans, 2020, Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: a systematic review and meta-analysis, Eur. J. Cardiothorac Surg, 57, 1051, 10.1093/ejcts/ezz339 Bendixen, 2016, Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial, Lancet Oncol, 17, 836, 10.1016/S1470-2045(16)00173-X Yang, 2019, A national analysis of long-term survival following thoracoscopic versus open lobectomy for stage I non-small-cell lung cancer, Ann. Surg, 269, 163, 10.1097/SLA.0000000000002342 Al-Ameri, 2018, Video-assisted thoracoscopic versus open thoracotomy lobectomy: a Swedish nationwide cohort study, J Thorac Dis, 10, 3499, 10.21037/jtd.2018.05.177 Yang, 2017, Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer: comparison of robotic, video-assisted thoracic surgery, and thoracotomy lobectomy, Ann Surg, 265, 431, 10.1097/SLA.0000000000001708 Chai, 2019, Thoracotomy versus video-assisted thoracoscopic resection of lung cancer: a protocol for a systematic review and meta-analysis, Medicine (Baltimore), 98, e14646, 10.1097/MD.0000000000014646 Brunelli, 2010, Recalibration of the revised cardiac risk index in lung resection candidates, Ann. Thorac Surg, 90, 199, 10.1016/j.athoracsur.2010.03.042 Kozower, 2010, STS database risk models: predictors of mortality and major morbidity for lung cancer resection, Ann. Thorac Surg, 90, 875, 10.1016/j.athoracsur.2010.03.115 Ball, 2019, Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial, Lancet Oncol, 20, 494, 10.1016/S1470-2045(18)30896-9 Nestle, 2020, Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): results of the phase II STRIPE trial, Radiother. Oncol, 148, 82, 10.1016/j.radonc.2020.03.018 Verstegen, 2015, Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy, J. Thorac. Oncol, 10, 1195, 10.1097/JTO.0000000000000576 Haasbeek, 2012, Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands, Ann. Oncol, 23, 2743, 10.1093/annonc/mds081 Zheng, 2014, Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis, Int. J. Radiat Oncol. Biol. Phys, 90, 603, 10.1016/j.ijrobp.2014.05.055 Bahig, 2017, Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise, J Thorac Dis, 9, 953, 10.21037/jtd.2017.03.80 Chang, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3 Rice, 2015, SABR vs surgery for NSCLC in the media, Lancet Oncol., 16, e422, 10.1016/S1470-2045(15)00230-2 Cao, 2015, Surgery versus SABR for resectable non-small-cell lung cancer, Lancet Oncol., 16, 10.1016/S1470-2045(15)00036-4 Hamaji, 2015, Surgery versus SABR for resectable non-small-cell lung cancer, Lancet Oncol., 16, e372, 10.1016/S1470-2045(15)00091-1 Wen, 2019, A propensity-matched analysis of outcomes of patients with clinical stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: a meta-analysis, J. Invest Surg, 32, 27, 10.1080/08941939.2017.1370519 Li, 2017, Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis, Oncol. Targets Ther, 10, 2885, 10.2147/OTT.S138701 Chen, 2018, Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies, Int. J. Radiat Oncol. Biol. Phys, 101, 186, 10.1016/j.ijrobp.2018.01.064 Ijsseldijk, 2020, Oncologic outcomes of surgery versus SBRT for non-small-cell lung carcinoma: a systematic review and meta-analysis, Clin. Lung Cancer de Baere, 2016, Percutaneous thermal ablation of primary lung cancer, Diagn. Interv. Imaging, 97, 1019, 10.1016/j.diii.2016.08.016 Detterbeck, 2013, Executive summary: diagnosis and management of lung cancer, 3rd ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 143, 7S, 10.1378/chest.12-2377 Dupuy, 2015, Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial, Cancer, 121, 3491, 10.1002/cncr.29507 Zhu, 2008, A systematic review of radiofrequency ablation for lung tumors, Ann. Surg. Oncol., 15, 1765, 10.1245/s10434-008-9848-7 Kim, 2012, Comparison between surgery and radiofrequency ablation for stage I non-small cell lung cancer, Eur J Radiol, 81, 395, 10.1016/j.ejrad.2010.12.091 Lencioni R., Crocetti L., Cioni R., Suh R., Glenn D., Regge D., et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–8. doi:10.1016/S1470-2045(08)70155-4. Chan, 2021, Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer (NSCLC): a systematic review and meta-analysis, Eur Radiol, 10.1007/s00330-020-07634-7 Li, 2018, Efficacy and safety of radiofrequency ablation for lung cancers: a systematic review and meta-analysis, Eur J Radiol, 100, 92, 10.1016/j.ejrad.2018.01.009 Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J. Clin. Oncol, 26, 3552, 10.1200/JCO.2007.13.9030 Scagliotti, 2003, Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer, J Natl Cancer Inst, 95, 1453, 10.1093/jnci/djg059 Strauss, 2008, Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups, J. Clin Oncol, 26, 5043, 10.1200/JCO.2008.16.4855 Gilligan, 2007, Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review, Lancet, 369, 1929, 10.1016/S0140-6736(07)60714-4 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, 29, 10.1093/annonc/mdy275 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 Faivre-Finn, 2021, Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial, J Thorac Oncol, 16, 860, 10.1016/j.jtho.2020.12.015 Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J. Med., 378, 1976, 10.1056/NEJMoa1716078 de Ruiter, 2020, Centralization of lung cancer surgery in the Netherlands: differences in care and survival of patients with stage I non-small cell lung cancer between hospitals with and without in-house lung cancer surgery, Acta Oncol, 1 de Ruiter, 2020, The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands, Lung Cancer, 144, 64, 10.1016/j.lungcan.2020.04.005 Dutch Institute for Clinical Auditing (DICA). DLCA jaarrapportage 2019. Available at: https://dica.nl/jaarrapportage-2019/dlca Accessed on October 3, 2020. Ten Berge, 2018, Dutch Lung Surgery Audit: a national audit comprising lung and thoracic surgery patients, Ann Thorac Surg, 106, 390, 10.1016/j.athoracsur.2018.03.049 Heineman, 2016, Clinical staging of stage I non-small cell lung cancer in the Netherlands-need for improvement in an era with expanding nonsurgical treatment options: data from the Dutch Lung Surgery Audit, Ann Thorac Surg, 102, 1615, 10.1016/j.athoracsur.2016.07.054 Wolff, 2018, Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non-small cell lung cancer, J. Thorac Oncol, 13, 689, 10.1016/j.jtho.2018.01.021 Fu, 2019, Merits and caveats of propensity scores to adjust for confounding, Nephrol. Dial Transplant, 34, 1629, 10.1093/ndt/gfy283 IJsseldijk, 2019, Survival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis, J. Thorac Oncol, 14, 583, 10.1016/j.jtho.2018.12.035 Bunn, 2004, Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy, Clin. Lung Cancer, 6, 85, 10.3816/CLC.2004.n.022 Reck, 2016, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Owen, 2018, Immunotherapy in surgically resectable non-small cell lung cancer, J. Thorac Dis, 10, S404, 10.21037/jtd.2017.12.93 Ghysen, 2019, Immunotherapy in patients with early stage resectable nonsmall cell lung cancer, Curr. Opin. Oncol, 31, 13, 10.1097/CCO.0000000000000497 Kim, 2016, Focal exposure of limited lung volumes to high-dose irradiation down-regulated organ development-related functions and up-regulated the immune response in mouse pulmonary tissues, BMC Genet, 17, 29, 10.1186/s12863-016-0338-9 Rutkowski, 2017, Changes in systemic immune response after stereotactic ablative radiotherapy. Preliminary results of a prospective study in patients with early lung cancer, Pol Arch. Intern. Med, 127, 245 McGee, 2018, Stereotactic ablative radiation therapy induces systemic differences in peripheral blood immunophenotype dependent on irradiated site, Int J. Radiat Oncol Biol Phys, 101, 1259, 10.1016/j.ijrobp.2018.04.038 Nagasaka, 2020, KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?, Cancer Treat Rev, 84, 10.1016/j.ctrv.2020.101974 Wu, 2020, Osimertinib in resected EGFR-mutated non-small-cell lung cancer, N Engl J Med, 383, 1711, 10.1056/NEJMoa2027071